Advertisement

Topics

Multiple Myeloma Research Foundation and Adaptive Biotechnologies Company Profile

01:49 EDT 22nd June 2018 | BioPortfolio

Adaptive Biotechnologies Corporation is a platform-based, diagnostic-driven company that leverages NGS to profile T-Cell and B-Cell Receptors. This breakthrough enables in-depth characterization of the adaptive immune system, which is the primary defense against cancer. By incorporating immunosequencing into clinical care, Adaptive can enhance the diagnosis, prognosis and monitoring of cancer patients. For more information, please visit AdaptiveBiotech.com.


News Articles [1568 Associated News Articles listed on BioPortfolio]

Sanofi to use Adaptive’s NGS-based assay in isatuximab multiple myeloma trials

Sanofi has agreed to use Adaptive Biotechnologies’ next generation sequencing (NGS) based assay in its active and future multiple myeloma (MM) trials with isatuximab.

Adaptive and Sanofi Collaborate to Use Adaptive’s clonoSEQ Assay in Active and Future Isatuximab Multiple Myeloma Trials

SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies, the leader in combining Next Generation Sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immu...

Multiple Myeloma Patients, Caregivers and Health Care Professionals Trekking to the Doorstep of ...

Eighteen hikers will take on this challenge in order to raise awareness and funds for multiple myeloma through the Multiple Myeloma Research Foundation, (MMRF) Read more...

AbbVie and the International Myeloma Foundation Partner to Study Role of a Genetic Mutation in Multiple Myeloma

AbbVie a research and development-based global biopharmaceutical company, and the International Myeloma Foundation (IMF) today announced they have entered into […] The post AbbVie and the Intern...

Multiple Myeloma Research Foundation (MMRF) Receives Highest Rating from Charity Navigator for Exceptional Fiscal Management

MMRF Honored for Fifteenth Year for Outstanding Stewardship of Donors’ Funds The Multiple Myeloma Research Foundation (MMRF) received a 4-star rating from Charity Nav...

Adaptive Biotechnologies and Microsoft Partner to Decode the Human Immune System to Improve Disease Diagnosis

SEATTLE–(BUSINESS WIRE)–Adaptive Biotechnologies, a leader in next-generation sequencing (NGS) of T- and B-cell receptors of the adaptive immune system, announced today their partnership w...

Microsoft, Adaptive Biotechnologies partner to develop diagnostic tool

Harlan RobinsAdaptive Biotechnologies and Microsoft have announced a partnership to develop a T-cell receptor-antigen map to assist in prompt detection and diagnosis of multiple diseases, including in...

Science Saturday: Genetic testing to enhance multiple myeloma treatment

Multiple myeloma is the second most common blood cancer, but most people haven?t heard of it until they or someone they know is diagnosed with the disease. March is Myeloma Action Month ? a time to fo...

PubMed Articles [3236 Associated PubMed Articles listed on BioPortfolio]

Multiple Myeloma Presenting as a Superscan on 68Ga-Pentixafor PET/CT.

A 60-year-old woman diagnosed with multiple myeloma was referred for Ga-pentixafor PET/CT for evaluation of the disease. Diffuse and intense radioactivity throughout the axial and proximal appendicula...

A historical perspective on milestones in multiple myeloma research.

The first well-documented case of multiple myeloma was reported in 1844 by Samuel Solly. In this article, I present a historical review of the disease. In particular, the review is focused on the main...

DANFIN functions as an inhibitor of transcription factor NF-κB and potentiates the antitumor effect of bortezomib in multiple myeloma.

Nuclear factor-κB (NF-κB) proteins are transcription factors that play key roles in regulating most immune responses and cell death. Constitutively active NF-κB has been shown to exhibit chemoresis...

Shall we treat smoldering multiple myeloma in the near future?

In recent years, several new drugs have been approved for the treatment of multiple myeloma. Many of these newer drugs are highly efficacious and less toxic than older chemotherapy drugs. In 2014, the...

The guidelines for the diagnosis and management of multiple myeloma in China (2017 revision): interpretation of treatment of relapsed/refractory multiple myeloma.

Clinical Trials [5246 Associated Clinical Trials listed on BioPortfolio]

Nivolumab + Lenalidomide + Dexamethasone In SMM

This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myelo...

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

The purpose of this research study is to determine the safety of CCI-779 and bortezomib, and the highest dose of this drug that can be given to people safely. We will also be looking at h...

Inflammatory Cytokines in Symptom Production in Multiple Myeloma

The goal of this research study is to learn about the pain and/or other symptoms that patients may experience during and after treatment for multiple myeloma (MM) and how these symptoms ma...

Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma

This research study is a Phase I/II clinical trial. It is done to determine the best doses that the investigational drug (P276-00) can be used safely. "Investigational" means that the dru...

Multiple Myeloma Molecular Monitoring Study

The investigators will track 250 multiple myeloma patients across Canada over time, using new lab tests to evaluate their blood and bone marrow, as they receive standard of care treatment....

Companies [3351 Associated Companies listed on BioPortfolio]

Multiple Myeloma Research Foundation and Adaptive Biotechnologies

Adaptive Biotechnologies Corporation is a platform-based, diagnostic-driven company that leverages NGS to profile T-Cell and B-Cell Receptors. This breakthrough enables in-depth c...

Multiple Myeloma Research Foundation (MMRF)

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2010, mo...

The Multiple Myeloma Research Foundation

Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 34 percent, one of the lowest of all cancers. In 2009, ap...

The Multiple Myeloma Research Foundation (MMRF)

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's dia...

GNS Healthcare and The Multiple Myeloma Research Foundation

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathyâ€...

More Information about "Multiple Myeloma Research Foundation and Adaptive Biotechnologies" on BioPortfolio

We have published hundreds of Multiple Myeloma Research Foundation and Adaptive Biotechnologies news stories on BioPortfolio along with dozens of Multiple Myeloma Research Foundation and Adaptive Biotechnologies Clinical Trials and PubMed Articles about Multiple Myeloma Research Foundation and Adaptive Biotechnologies for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Multiple Myeloma Research Foundation and Adaptive Biotechnologies Companies in our database. You can also find out about relevant Multiple Myeloma Research Foundation and Adaptive Biotechnologies Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...


Corporate Database Quicklinks



Searches Linking to this Company Record